THERACOM WINS DISPENSING PACT FOR GLUCOWATCH G2 BIOGRAPHER.
Sankyo Pharma is responsible for marketing and distributing the GlucoWatch G2 Biographer in the U.S. through an agreement with the product's developer and manufacturer, Cygnus Inc. Cygnus provides technical support.
The device is worn like a watch, and is the second-generation model of the first and only glucose monitoring system that provides readings continuously, automatically and non-invasively. The GlucoWatch G2 Biographer, available by prescription to children and adolescents (ages 7-17) and to adults (age 18 and older), offers significant technological advancements that provide diabetes patients and their physicians with greater convenience and efficiency, and help them make better-informed decisions in managing the disease.
"We are excited about this opportunity to make the GlucoWatch G2 Biographer more accessible and convenient for physicians to prescribe and patients to use," said David D. Halbert, AdvancePCS chairman and CEO. "Our TheraCom subsidiary is uniquely positioned to offer one-stop reimbursement and dispensing services that will improve patients' access to valuable specialty products such as this one."
Under terms of the contract, TheraCom will provide retail pharmacy distribution services and mail order distribution fulfillment directly to GlucoWatch G2 Biographer patients. It also will be responsible for claims processing and reimbursement, as well as toll-free telephone information and information management services.
"Sankyo Pharma is pleased to be working with TheraCom to ensure a smooth fulfillment process for the patients who need the GlucoWatch G2 Biographer," said Joseph P. Pieroni, Sankyo Pharma president.
Additional information about the GlucoWatch G2 Biographer can be obtained by calling the toll-free number 1-866-GLWATCH or by visiting http://www.glucowatch.com.
TheraCom, a subsidiary of AdvancePCS, the nation's leading health improvement company, is a specialty pharmacy business with substantial experience providing distribution and related services to the biotechnology industry. Services include product coverage advocacy, insurance verification, reimbursement processing, pharmacist counseling and intervention, clinical and dosage monitoring, adherence counseling, nurse training, and in-home nursing coordination. The company also provides Internet, marketing, advertising and product launch support services. Based in Bethesda, Md., TheraCom is a licensed pharmacy offering national coverage, as well as a licensed wholesaler for distribution orders.
AdvancePCS is the nation's largest independent provider of health improvement services, touching the lives of more than 75 million health plan members and managing approximately $28 billion in annual prescription drug spending. AdvancePCS offers health plans a wide range of health improvement products and services designed to improve the quality of care delivered to health plan members and manage costs.
The company's capabilities include integrated mail service and retail pharmacy networks, innovative clinical services, customized disease management programs, specialty pharmacy, clinical trials and outcomes research, information management, prescription drug services for the uninsured, and online health information for consumers. AdvancePCS clients include Blue Cross and Blue Shield organizations, insurance companies and HMOs, Fortune 500 employers, Taft-Hartley groups, state and local governments, and other health plan sponsors.
AdvancePCS is ranked by Fortune magazine as one of America's 100 fastest-growing public companies and is included on the Forbes Platinum 400 list of best big companies. AdvancePCS earned the number two spot on the Barron's 500 list of best performing companies. AdvancePCS is both a Fortune 500 and Fortune Global 500 company.
For more information, visit www.advancepcs.com or call 469/524-4729 or visit http://www.thera.com.
|Printer friendly Cite/link Email Feedback|
|Publication:||Biotech Equipment Update|
|Date:||Nov 1, 2002|
|Previous Article:||NOVARE DEBUTS CYGNET DUAL-ACTION AORTIC CROSS-CLAMPS.|
|Next Article:||CMS USES BIOZ FOR DIAGNOSIS/TREATMENT OF HEART DISEASE.|
|* FDA approves new glucose test for diabetic patients.|
|On the horizon: better glucose testing.|